Botulinum toxin type A is used in neurology for chronic migraine, dystonia, spasticity, blepharospasm, hemifacial spasm and several other neurological conditions. Successful treatment depends on accurate diagnosis, appropriate selection of muscles or injection sites, and an individualized treatment plan.
Botulinum toxin therapy involves local injections of small amounts of botulinum toxin into selected muscles or other anatomical sites. At the neuromuscular junction, the toxin temporarily reduces acetylcholine release and therefore decreases excessive muscle activity.
This mechanism explains its established role in conditions characterized by abnormal muscular contractions, including dystonia, blepharospasm, hemifacial spasm and spasticity. In chronic migraine and some pain disorders, its therapeutic effect is more complex and also involves modulation of pain signaling.
The treatment is often informally referred to as “Botox”, but Botox is the brand name of one botulinum toxin preparation. Several botulinum toxin type A products are used in neurological practice, and their dosing units are not interchangeable.
Treatment protocols differ substantially between migraine, dystonia, spasticity and other neurological disorders. The therapeutic goals, injection sites and doses are therefore selected separately for each condition and each patient.
Botulinum toxin is used for preventive treatment of chronic migraine. Injections are performed according to a defined pattern across the head and neck and are repeated at appropriate intervals. It may be considered when frequent headache persists despite adequate acute and preventive treatment strategies.
Botulinum toxin for chronic migraine →In focal and segmental dystonia, botulinum toxin can reduce abnormal muscle contractions, pain and involuntary postures. Muscle selection is based on the clinical pattern of dystonia and the individual treatment goals.
Botulinum toxin therapy for dystonia →Botulinum toxin is used for focal and multifocal spasticity after stroke, in multiple sclerosis and in other disorders of the central nervous system. Treatment goals may include improved function, reduction of pain and spasms, easier care and prevention of secondary complications.
Botulinum toxin therapy for spasticity →Medication remains the main treatment for classical trigeminal neuralgia. Botulinum toxin may be considered in selected patients when conventional treatment is insufficiently effective or poorly tolerated.
Botulinum toxin for trigeminal neuralgia →Cervical dystonia causes involuntary contractions of neck muscles, abnormal head posture, tremor and frequently pain. Botulinum toxin is one of the main symptomatic treatments for this condition.
Involuntary contractions around the eyes may cause excessive blinking, forceful eyelid closure and significant functional visual impairment. Local botulinum toxin injections can reduce abnormal muscle activity.
Hemifacial spasm produces involuntary contractions on one side of the face. Following diagnostic assessment, botulinum toxin can provide effective symptomatic control, while the underlying cause and need for additional investigation should also be considered.
Botulinum toxin is also used to reduce excessive salivation in several neurological disorders and for selected additional focal movement disorders. Indications are determined individually after neurological assessment.
Botulinum toxin therapy works best when the diagnosis, clinical pattern and treatment goal are clearly defined. A neurological assessment is therefore required before planning the procedure.
In dystonia, the physician identifies the muscles responsible for abnormal movements and postures. In spasticity, it is important to determine which components of increased muscle tone actually interfere with function. In headache and facial pain, the diagnosis must first be confirmed before botulinum toxin treatment is considered.
The diagnosis, symptoms, previous treatment and expected outcome are reviewed.
Injection sites, target muscles and the individual dosing plan are selected.
Small amounts of botulinum toxin are injected locally. The procedure is usually outpatient.
The clinical effect is assessed and the next treatment cycle can be adjusted accordingly.
Botulinum toxin does not act immediately. In movement disorders, improvement usually begins within several days and develops gradually.
The duration of benefit depends on the indication, preparation, dose and individual response. Treatment is therefore commonly repeated, with intervals determined by clinical need and previous response.
In chronic migraine, response is assessed primarily by changes in the number of headache and migraine days, use of acute medication and the overall impact of migraine on daily life.
Most adverse effects are related to the injection site or temporary spread of the effect to nearby muscles. Local discomfort, bruising or temporary weakness may occur.
Potential adverse effects depend on the area treated. For example, injections around the eyes may occasionally cause temporary eyelid drooping, while treatment of selected neck muscles can sometimes cause temporary swallowing difficulty.
Before treatment, patients should inform the neurologist about neuromuscular disorders, pregnancy or breastfeeding, current medications and previous botulinum toxin injections or unusual reactions.
Dr Lidiia Prakhova is a neurologist with extensive clinical experience in the diagnosis and treatment of neurological disorders. Her clinical practice includes migraine, dystonia, spasticity and other conditions for which botulinum toxin may be indicated.
Patients in Israel can undergo neurological evaluation to determine whether botulinum toxin therapy is appropriate, what treatment goal should be defined and which treatment strategy is most suitable.
If you have already received botulinum toxin treatment, it is useful to bring information about the preparation, dose, injection pattern and response to the previous procedure.
Botox is the brand name of one botulinum toxin preparation. Different botulinum toxin type A products are used in neurology, and their dosing units are not directly interchangeable.
Yes, in many neurological conditions the effect is temporary. If treatment is effective, repeat procedures are usually planned according to the diagnosis and individual clinical response.
This depends on the diagnosis and available medical information. The indication, treatment goals and injection plan need to be established first.
Not necessarily. In some disorders it is one of the main symptomatic treatments, while in others it is used as part of a broader treatment strategy.
No. In addition to dystonia and spasticity, it is used for chronic migraine, blepharospasm, hemifacial spasm, sialorrhea and selected pain disorders.
A consultation can clarify the diagnosis, determine whether botulinum toxin therapy is appropriate and establish realistic treatment goals.
Book a consultation